KF1601, New Drug Candidate for Chronic Myeloid Leukemia, Proves Drug Resistance Suppression and Less Side Effects
May 25, 2025
Uijeongbu Eulji University Hospital said Professor Kim Dong-wook's team of hematology department proved that KF1601, a candidate for next-generation chronic myelogenous leukemia treatment, overcomes existing drug resistance and reduces side effects.
According to Uijeongbu Eulji Hospital, Professor Kim Dong-wook's team (Director of the Leukemia Omics Research Institute at Eulji University) proved this through a preclinical study of KF1601 in collaboration with Professor Lee Munopji and Professor Park Hyun-woo of Yonsei University's Department of Biochemistry.
KF1601, developed by Immunofozi, is a Tyrosine Kinase Inhibitor (TKI) class targeted treatment.
It is known to prevent cancer cell growth by inhibiting tyrosine kinase enzyme activity that increases white blood cells and platelets in BCR::ABL1, the cause of leukemia.
In this study, the professor's team demonstrated that KF1601 effectively suppresses the T315I mutation gene that is resistant to existing treatments, thereby lowering the risk of recurrence and the possibility of treatment failure.
In particular, it was also found that it has the effect of inhibiting the signaling pathway of the gene mutation FLT3, which is involved in the acute phase of accelerating cancer progression.
In addition, it also confirmed that the risk of side effects such as heart failure, hepatotoxicity, and blood clots is lower than that of existing drugs, raising expectations for next-generation treatments that reduce the burden of long-term use.
KF1601 has already been designated as an Orphan Drug (ODD) by the U.S. Food and Drug Administration (FDA) in 2023, and in Korea, it has obtained approval for the Phase 1 clinical trial plan (IND) from the Ministry of Food and Drug Safety, and is about to enter the clinical trial in earnest.
Chronic myeloid leukemia is a blood cancer that occurs when myelocyte cells make white blood cells. About 20% of adult myeloid leukemia patients in Korea were found to be this.
Currently, it is estimated that there are about 8,000 patients with chronic myelogenous leukemia in Korea, and it is known that there are about 500 new patients per year alone.
Existing treatments need to be taken for life, and there is a high demand for the development of new treatments as it is difficult to continue treatment due to resistance and adverse reactions during long-term exposure.
Professor Kim said, "KF1601 is a treatment that shows the potential to exceed the limits of chronic myelogenous leukemia treatment" and added, "Drug-induced side effects such as thrombotic and inflammatory reactions are also expected to be significantly reduced compared to conventional TKI drugs." he said.
Meanwhile, the paper containing the results of this study was published in the latest issue of the world-renowned journal of cancer biology, 'Molecular Cancer (IF=37.3)'.
According to Uijeongbu Eulji Hospital, Professor Kim Dong-wook's team (Director of the Leukemia Omics Research Institute at Eulji University) proved this through a preclinical study of KF1601 in collaboration with Professor Lee Munopji and Professor Park Hyun-woo of Yonsei University's Department of Biochemistry.
KF1601, developed by Immunofozi, is a Tyrosine Kinase Inhibitor (TKI) class targeted treatment.
It is known to prevent cancer cell growth by inhibiting tyrosine kinase enzyme activity that increases white blood cells and platelets in BCR::ABL1, the cause of leukemia.
In this study, the professor's team demonstrated that KF1601 effectively suppresses the T315I mutation gene that is resistant to existing treatments, thereby lowering the risk of recurrence and the possibility of treatment failure.
In particular, it was also found that it has the effect of inhibiting the signaling pathway of the gene mutation FLT3, which is involved in the acute phase of accelerating cancer progression.
In addition, it also confirmed that the risk of side effects such as heart failure, hepatotoxicity, and blood clots is lower than that of existing drugs, raising expectations for next-generation treatments that reduce the burden of long-term use.
KF1601 has already been designated as an Orphan Drug (ODD) by the U.S. Food and Drug Administration (FDA) in 2023, and in Korea, it has obtained approval for the Phase 1 clinical trial plan (IND) from the Ministry of Food and Drug Safety, and is about to enter the clinical trial in earnest.
Chronic myeloid leukemia is a blood cancer that occurs when myelocyte cells make white blood cells. About 20% of adult myeloid leukemia patients in Korea were found to be this.
Currently, it is estimated that there are about 8,000 patients with chronic myelogenous leukemia in Korea, and it is known that there are about 500 new patients per year alone.
Existing treatments need to be taken for life, and there is a high demand for the development of new treatments as it is difficult to continue treatment due to resistance and adverse reactions during long-term exposure.
Professor Kim said, "KF1601 is a treatment that shows the potential to exceed the limits of chronic myelogenous leukemia treatment" and added, "Drug-induced side effects such as thrombotic and inflammatory reactions are also expected to be significantly reduced compared to conventional TKI drugs." he said.
Meanwhile, the paper containing the results of this study was published in the latest issue of the world-renowned journal of cancer biology, 'Molecular Cancer (IF=37.3)'.
|
This article was translated by Naver AI translator.
